Big pharma backed away from brain drugs. Is a return in sight?

Industry watchers foresee big pharma mounting a return to neuroscience in the next few years, lured by emerging treatments for epilepsy, mood disorders and ...

Bristol Myers' neuroscience research head explains the big ...

Bristol Myers' neuroscience research head explains the big pharma's return to brain drugs ... In a wide-ranging interview, Bristol Myers' Ken ...

Neuroscience under threat as Big Pharma backs off - Reuters

LONDON (Reuters) - Scientists worried by waning commitment from major drugmakers to brain research warn the prospect for new drugs to treat ...

Pharma Ins and Outs Neuroscience - Krzysztof Potempa - LinkedIn

Pfizer and Merck, as well as the French company Sanofi, also pulled back on research into brain disorders. Rather than abandon neuroscience, ...

Leo Adalbert on X: "Huge unmet needs, with many diseases ...

Huge unmet needs, with many diseases becoming a public health crisis -- LJA Big pharma backed away from brain drugs. Is a return in sight?

Brain Control Through Big Pharma | Drugs | Cosmetic Neurology

Brain Control Through Big Pharma - Forget about life-work-balance. A new generation of drugs promise unlimited increases in productivity ...

Broken Deals: 4 Pharma Assets Returned to Biotech This Year

On top of the bad PR that comes with a returned asset, it usually brings uncertainties of how the smaller biotech will finance the drug to get ...

The Need for New Approaches in CNS Drug Discovery

CNS drugs in general have higher failure rates than non-CNS drugs, both preclinically and clinically, and in some areas, such as the major neurodegenerative ...

Don't call it a comeback: Biotech's CNS resurgence forges Big ...

In recent years, however, evidence across the industry suggests the brain is back. ... Big Pharma brethren were backing down. Now, as the industry ...

Alzheimer's disease drug development and the problem of the blood ...

Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small molecule drugs, and ∼100% of ...

Merck is back in Alzheimer's saddle with $1B+ Cerevance pact

Another Big Pharma is entering—or rather re-entering—the Alzheimer's ring. Merck & Co. has signed a billion-dollar biobucks deal with ...

Why drug development is slowing down – and what to do about it

In recent years, the percent of medicines that needed to be pulled from the market has increased as much as 25%. In 2022, the FDA approved 37 ...

Is big pharma backtracking from neurosciences? - BioSpectrum Asia

In 2018, Pfizer announced that the firm is pulling out of neuroscience drug discovery and early development, and cutting 300 positions in its ...

Martin Shkreli, the Bad Boy of Pharmaceuticals, Hits Back

His name is on two patents held by his former company, Retrophin, for drugs to treat the degenerative brain disease afflicting those North ...

Medicines for the Mind: Policy-Based “Pull” Incentives for Creating ...

One way to do this that would not require upfront funding is to change the policies that regulate market returns for the most-needed ...

Pharma goes to space - C&EN - American Chemical Society

Researchers are capitalizing on microgravity in space to accelerate drug discovery and development.

Special Report: Big Pharma's stalled R&D machine - Reuters

"It used to be a job for life. Now it's a job until the next restructuring." Across the western world, Big Pharma is cutting back on the number ...

The top 10 pharma drug ad spenders for 2022

Some in the top 10 did spend big on other promotion methods, with Biohaven's (now Pfizer's) migraine drug Nurtec and AbbVie's Botox being two of ...

The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't ...

No wonder Big Pharma seems to be turning its back on CNS drugs. Since 2011, GSK, AstraZeneca and Novartis have announced closures of ...

The 10 highest value R&D projects in biopharma - Fierce Biotech

Eli Lilly's Alzheimer's med donanemab also stands out because it's one Big Pharma project that was developed in-house. Lilly didn't have to buy ...